Towards a new approach to immunotherapy in the treatment of skin cancer – the ARC Foundation provides long-term support Over the past 10 years, immunotherapy has significantly improved the management of patients with metastatic melanoma, one of the rarest but...
Obesity and melanoma: a new link Melanoma p16INK4A Obesity CDKN2A Adipocytes beta-catenin extracellular vesicle Laurence Niéto – MELASPHINX Team – Métabolisme du céramide dans le mélanome : des mécanismes moléculaires à l’immunothérapie Obesity is a...
A new immunotherapy strategy for melanoma patients. Anti-TNF Anti-PD-1 Anti-CTLA-4 melanoma Clinical trial Bruno Ségui a Nicolas Meyer – Equipe “MELASPHINX : Sphingolipid metabolism: From basic mechanisms to immunotherapy Melanoma is a skin cancer with a poor...
Reprogramming a family of lipids to increase the effectiveness of melanoma immunotherapy. ceramide metabolism Anti PD-1 anti-CTLA-4 melanoma immunotherapy melanoma resistance Bruno Ségui & Céline Colacios CRCT team : Ceramide metabolism in melanoma Immunotherapy...
To improve your browsing experience. Cookies provide information on how the site is used: statistics such as the number of visitors, the average length of visits or the number of pages viewed. On the other hand, disabling cookies may prevent you from using certain features, such as sharing content via social networks.
You can adjust all your cookie settings by navigating the tabs on the left.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This site uses Google Analytics to collect anonymous information such as the number of visitors to the site and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!